(Q35483221)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Francesca Gilli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

A Sala

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S Malucchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

F Marnetto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Caldano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Di Sapio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Capobianco

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neurology, Neurosurgery and Psychiatry

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

1294-1299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

31 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Mechanisms of action of interferon-beta in multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Lymphocyte responses and cytokines

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1739245

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

26 September 2018

1 reference

12 December 2020

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

12 December 2020

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

12 December 2020

Mechanisms for regulation of cellular responsiveness to human IFN-beta1a

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

J. Stephen Fink, MD, PhD (1950-2002)

1 reference

12 December 2020

Quantitation of neutralization of interferon by antibody

1 reference

12 December 2020

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta

1 reference

12 December 2020

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

12 December 2020

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B

1 reference

12 December 2020

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.2004.037259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15314118%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference